These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 11707522)
21. Pondering the promyelocytic leukemia protein (PML) puzzle: possible functions for PML nuclear bodies. Borden KL Mol Cell Biol; 2002 Aug; 22(15):5259-69. PubMed ID: 12101223 [No Abstract] [Full Text] [Related]
22. Interferon gamma regulates accumulation of the proteasome activator PA28 and immunoproteasomes at nuclear PML bodies. Fabunmi RP; Wigley WC; Thomas PJ; DeMartino GN J Cell Sci; 2001 Jan; 114(Pt 1):29-36. PubMed ID: 11112687 [TBL] [Abstract][Full Text] [Related]
23. Disruption of PML-associated nuclear bodies mediated by the human cytomegalovirus major immediate early gene product. Wilkinson GW; Kelly C; Sinclair JH; Rickards C J Gen Virol; 1998 May; 79 ( Pt 5)():1233-45. PubMed ID: 9603339 [TBL] [Abstract][Full Text] [Related]
24. Role of the promyelocytic leukemia body in the dynamic interaction between the androgen receptor and steroid receptor coactivator-1 in living cells. Rivera OJ; Song CS; Centonze VE; Lechleiter JD; Chatterjee B; Roy AK Mol Endocrinol; 2003 Jan; 17(1):128-40. PubMed ID: 12511612 [TBL] [Abstract][Full Text] [Related]
25. Repression of PML nuclear body-associated transcription by oxidative stress-activated Bach2. Tashiro S; Muto A; Tanimoto K; Tsuchiya H; Suzuki H; Hoshino H; Yoshida M; Walter J; Igarashi K Mol Cell Biol; 2004 Apr; 24(8):3473-84. PubMed ID: 15060166 [TBL] [Abstract][Full Text] [Related]
26. Ret finger protein is a normal component of PML nuclear bodies and interacts directly with PML. Cao T; Duprez E; Borden KL; Freemont PS; Etkin LD J Cell Sci; 1998 May; 111 ( Pt 10)():1319-29. PubMed ID: 9570750 [TBL] [Abstract][Full Text] [Related]
27. The major immediate-early proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt PML-associated nuclear bodies at very early times in infected permissive cells. Ahn JH; Hayward GS J Virol; 1997 Jun; 71(6):4599-613. PubMed ID: 9151854 [TBL] [Abstract][Full Text] [Related]
28. Apoptin is modified by SUMO conjugation and targeted to promyelocytic leukemia protein nuclear bodies. Janssen K; Hofmann TG; Jans DA; Hay RT; Schulze-Osthoff K; Fischer U Oncogene; 2007 Mar; 26(11):1557-66. PubMed ID: 16924230 [TBL] [Abstract][Full Text] [Related]
29. The tumor suppressor PML specifically accumulates at RPA/Rad51-containing DNA damage repair foci but is nonessential for DNA damage-induced fibroblast senescence. Münch S; Weidtkamp-Peters S; Klement K; Grigaravicius P; Monajembashi S; Salomoni P; Pandolfi PP; Weißhart K; Hemmerich P Mol Cell Biol; 2014 May; 34(10):1733-46. PubMed ID: 24615016 [TBL] [Abstract][Full Text] [Related]
30. Recruitment of human cyclin T1 to nuclear bodies through direct interaction with the PML protein. Marcello A; Ferrari A; Pellegrini V; Pegoraro G; Lusic M; Beltram F; Giacca M EMBO J; 2003 May; 22(9):2156-66. PubMed ID: 12727882 [TBL] [Abstract][Full Text] [Related]
31. [Promyelocytic leukaemia protein and defect in transforming growth factor-beta signal pathway in acute promyelocytic leukaemia]. Fuchs O; Provazníková D; Peslová G Cas Lek Cesk; 2005; 144(2):90-4. PubMed ID: 15807293 [TBL] [Abstract][Full Text] [Related]
32. Promyelocytic leukemia nuclear bodies provide a scaffold for human polyomavirus JC replication and are disrupted after development of viral inclusions in progressive multifocal leukoencephalopathy. Shishido-Hara Y; Higuchi K; Ohara S; Duyckaerts C; Hauw JJ; Uchihara T J Neuropathol Exp Neurol; 2008 Apr; 67(4):299-308. PubMed ID: 18379438 [TBL] [Abstract][Full Text] [Related]
33. Physical and functional link of the leukemia-associated factors AML1 and PML. Nguyen LA; Pandolfi PP; Aikawa Y; Tagata Y; Ohki M; Kitabayashi I Blood; 2005 Jan; 105(1):292-300. PubMed ID: 15331439 [TBL] [Abstract][Full Text] [Related]
34. Disruption of PML-associated nuclear bodies during human cytomegalovirus infection. Kelly C; Van Driel R; Wilkinson GW J Gen Virol; 1995 Nov; 76 ( Pt 11)():2887-93. PubMed ID: 7595400 [TBL] [Abstract][Full Text] [Related]
35. Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. Adamson AL; Kenney S J Virol; 2001 Mar; 75(5):2388-99. PubMed ID: 11160742 [TBL] [Abstract][Full Text] [Related]
36. PML bodies control the nuclear dynamics and function of the CHFR mitotic checkpoint protein. Daniels MJ; Marson A; Venkitaraman AR Nat Struct Mol Biol; 2004 Nov; 11(11):1114-21. PubMed ID: 15467728 [TBL] [Abstract][Full Text] [Related]
37. In situ SUMOylation analysis reveals a modulatory role of RanBP2 in the nuclear rim and PML bodies. Saitoh N; Uchimura Y; Tachibana T; Sugahara S; Saitoh H; Nakao M Exp Cell Res; 2006 May; 312(8):1418-30. PubMed ID: 16688858 [TBL] [Abstract][Full Text] [Related]
38. Functional interactions between the Epstein-Barr virus BZLF1 protein and the promyelocytic leukemia protein. Bowling BL; Adamson AL Virus Res; 2006 May; 117(2):244-53. PubMed ID: 16307818 [TBL] [Abstract][Full Text] [Related]
39. Interactions between coilin and PIASy partially link Cajal bodies to PML bodies. Sun J; Xu H; Subramony SH; Hebert MD J Cell Sci; 2005 Nov; 118(Pt 21):4995-5003. PubMed ID: 16219678 [TBL] [Abstract][Full Text] [Related]
40. The human cytomegalovirus IE2 and UL112-113 proteins accumulate in viral DNA replication compartments that initiate from the periphery of promyelocytic leukemia protein-associated nuclear bodies (PODs or ND10). Ahn JH; Jang WJ; Hayward GS J Virol; 1999 Dec; 73(12):10458-71. PubMed ID: 10559364 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]